SanRx Announces Initiation of FDA-Certified Efficacy Trial of ImmunoPterin for Arthritis

SAN DIEGO - Sept. 23, 2014 - PRLog -- San Diego, Calif. (September 23, 2014) SanRx announces the start of its FDA-certified efficacy trial of ImmunoPterin, an investigational immune modulator, to seek it’s efficacy against arthritis. The trial is a randomized, double-blind, active-control, parallel-group study in subjects with active arthritis.

“The initiation of a FDA-certified efficacy study is an important event for arthritis patients,” said Phillip Moheno, PhD, President and Chief Scientist at SanRx. “ImmunoPterin is specifically designed to produce immune-supporting pterins. In our pilot clinical study (http://www.immunopterin.com/pdf/IPSurveyResults070113pmrev.pdf), ImmunoPterin has shown some positive effects reported including reduced pain and stiffness of arthritis.”

“Users of ImmunoPterin have consistently reported less pain and stiffness due to their arthritis symptoms,” said Moheno. “As with other health imbalances people experience, arthritis is one often treated with drugs that cause side effects, in some cases very dangerous ones. Because ImmunoPterin is a vitamin+GRAS (generally regarded as safe) dietary supplement, it has no side effects and is completely safe to use daily.”

About SanRx

Based in San Diego, California, SanRx is the leading developer of immune-supporting compounds based on the naturally-occurring human small molecule "pterin." Preclinical testing by reputable third-party laboratories substantiates that the compounds discovered by SanRx provide a strong potential to support the human immune system against a number of immune imbalance conditions without the side effects or high cost of traditional therapies. For more information, visit sanrx.com (http://www.sanrx.com/).

Company Contact:
Dr Phillip Moheno, SanRx President and Chief Scientist, phil.moheno@sanrx.com, 858.344.9778

Media Contact:
Dara Feldman, Mission Partners, dara@yourmissionpartners.com, 310.980.0442